Equitable Holdings Inc. Invests $963,000 in Revolution Medicines, Inc. $RVMD

Equitable Holdings Inc. acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,140 shares of the company's stock, valued at approximately $963,000.

Other large investors have also modified their holdings of the company. State of Wyoming purchased a new stake in shares of Revolution Medicines during the second quarter worth about $1,769,000. Handelsbanken Fonder AB raised its position in shares of Revolution Medicines by 243.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company's stock valued at $39,755,000 after acquiring an additional 150,500 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Revolution Medicines during the fourth quarter worth $9,231,000. Assenagon Asset Management S.A. acquired a new stake in Revolution Medicines during the second quarter worth about $37,547,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Revolution Medicines during the 2nd quarter worth approximately $112,566,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Stock Down 6.0%

Revolution Medicines stock opened at $207.88 on Friday. Revolution Medicines, Inc. has a twelve month low of $37.56 and a twelve month high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The firm has a market cap of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39. The firm's 50 day moving average price is $193.33 and its two-hundred day moving average price is $148.59.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) EPS. On average, research analysts predict that Revolution Medicines, Inc. will post -8.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on RVMD shares. Oppenheimer lifted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an "outperform" rating in a research report on Thursday. Weiss Ratings restated a "sell (d-)" rating on shares of Revolution Medicines in a report on Friday, July 17th. Piper Sandler increased their target price on shares of Revolution Medicines to $172.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $248.00 target price on shares of Revolution Medicines in a report on Thursday. Finally, Evercore reaffirmed an "outperform" rating and issued a $320.00 price objective on shares of Revolution Medicines in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $198.89.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the sale, the chief financial officer owned 123,269 shares of the company's stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Margaret A. Horn sold 29,600 shares of the firm's stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total value of $4,739,552.00. Following the completion of the transaction, the chief operating officer directly owned 154,647 shares of the company's stock, valued at approximately $24,762,077.64. This trade represents a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 212,497 shares of company stock worth $38,206,486. Insiders own 7.60% of the company's stock.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source